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Abstract: Viruses are underrepresented as targets in pharmacological screening efforts, given the
difficulties of devising suitable cell-based and biochemical assays. In this study we found that a
pre-fractionated organic extract of the Red Sea sponge Amphimedon chloros was able to inhibit the West
Nile Virus NS3 protease (WNV NS3). Using liquid chromatography–mass spectrometry (LC-MS)
and nuclear magnetic resonance (NMR) spectroscopy, the identity of the bioactive compound was
determined as a 3-alkylpyridinium with m/z = 190.16. Diffusion Ordered Spectroscopy (DOSY)
NMR and NMR relaxation rate analysis suggest that the bioactive compound forms oligomers of
up to 35 kDa. We observed that at 9.4 µg/mL there was up to 40–70% inhibitory activity on WNV
NS3 protease in orthogonal biochemical assays for solid phase extracts (SPE) of A. chloros. However,
the LC-MS purified fragment was effective at inhibiting the protease up to 95% at an approximate
amount of 2 µg/mL with negligible cytotoxicity to HeLa cells based on a High-Content Screening
(HCS) cytological profiling strategy. To date, 3-alkylpyridinium type natural products have not been
reported to show antiviral activity since the first characterization of halitoxin, or 3-alkylpyridinium,
in 1978. This study provides the first account of a 3-alkylpyridinium complex that exhibits a proposed
antiviral activity by inhibiting the NS3 protease. We suggest that the here-described compound can
be further modified to increase its stability and tested in a cell-based assay to explore its full potential
as a potential novel antiviral capable of inhibiting WNV replication.
Keywords: halitoxin; antiviral; Red Sea; bioprospecting; West Nile Virus; NS3 protease; High-Content
Screening (HCS)
1. Introduction
Viruses are underrepresented as targets in pharmacological screening efforts. This is because
cell-based assays of viruses are innately complex and require biochemical assay counterscreens causing
them to be time consuming and expensive. These challenges cause antiviral assays to be prioritized
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in the industry setting in favor of the most pressing viruses such as human immunodeficiency virus
(HIV) and hepatitis C virus (HCV) [1]. West Nile fever is considered a neglected tropical disease.
Its causative agent, West Nile Virus (WNV), belongs to the Flaviviridae family together with the
hepatitis C virus (HCV). WNV is transmitted by Culex spp. mosquitoes. Symptoms of the disease
include fever, headache, body aches, skin rash, swollen lymph glands and in extreme cases, encephalitis
or meningitis [2]. The virus is mainly endemic to Africa, the Middle East and the area around the
Mediterranean Sea [3], but remains a threat to other countries when the infected hosts, both mosquitoes
and humans, travel. HCV currently has more than two dozen prospective antivirals in various clinical
phases, whereas WNV has none. However, WNV is well-defined biochemically and commercial
biochemical assays are available for screening purposes [4]. This allows for the rapid identification of
novel inhibitors from new sources.
The replication cycle of the WNV begins as the 45–50 nm enveloped, icosahedral nucleocapsid
binds to unknown receptors on the host cell. Receptor-mediated endocytosis brings the virion into
the cell. The positive single-stranded 11 kb RNA genome is uncoated and can be directly translated
by the host machinery into single long polyproteins in the rough endoplasmic reticulum (ER) [5].
The polyprotein contains three structural proteins (capsid, pre-membrane, and envelope) and seven
non-structural (NS) proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, NS5). The polyprotein must
be cleaved by the NS3 protease in order to produce the individual proteins required for replication
and particle maturation [6]. A molecule that can inhibit the NS3 protease will prohibit subsequent
replication, packaging, and spread of the virus within the host organism. Viral proteases are good drug
targets as exemplified by the ten clinically approved HIV protease inhibitors [7] and two approved
inhibitors of the HCV NS3 protease [8]. As a result, the WNV NS3 protease is a promising target
for screening efforts directed at inhibiting WNV replication [9]. The WNV NS3 protease is a serine
protease with a marked homology to the four serotypes of the dengue virus (DENV) NS3 protease,
where all have been described to have an active site that is relatively flat and highly exposed [6],
two features that pose a problem for identifying inhibitors. As a result, the non-competitive binding
site has also become a targeted domain.
A well-represented group of marine natural products with unique structures are the halitoxins.
These 3-alkylpyridinium molecules have acquired a number of hyponyms since the first isolation
of the parent molecule, halitoxin, from a Haliclona sp. sponge [10]. The first compound from
Haliclona was investigated for its characteristic ichthyotoxicity. Accounts of the halitoxin family
bioactivity since the first isolation include epidermal growth factor (EGF) receptor activation [11],
histone deacetylase inhibition [12], acetylcholinesterase inhibition and selective toxicity toward
non-small cell lung cancer cells [13,14], dorsal root ganglion (DRG) neuron activity [15], antifungal [16],
antimycobacterial, and antimicrobial [17] activity as well as cytotoxicity [10,18]. The caveat to
cytotoxicity is that 3-alkylpyridiniums can be found as cyclic or linear compounds, as monomers or
as polymeric alkylpyridiniums (poly-APS), where the cytotoxicity of the molecules is both size-
and dose-dependent [17]. Interestingly, macrocylic compounds in general are noted for their
flexibility, high potency, selectivity, solubility, lipophilicity, membrane permeability, oral bioavailability,
and metabolic stability and function as chemotherapeutics, immunosuppressants, antifungals,
antiparasitics, antibacterials, and antivirals [19]. However, to date none of the various forms of
a 3-alkylpyridinium natural product have been reported to display any antiviral activity.
In this study a sponge-derived natural product library was screened for the ability to inhibit
the WNV NS3 protease. This led to the identification of a fraction from the Red Sea sponge,
Amphimedon chloros, that displays the ability to inhibit the WNV NS3 protease in vitro. This activity is
attributed to the 3-alkylpyridinium derivative present in the active fraction, which in its simplest form,
consists of an alkyl group connected to C-3 of a pyridine ring. An investigation into halitoxin and
the 3-alkyl- pyridinium class of compounds revealed the long-standing problem of how to ascertain
the relative molecular size of these compounds. This question was addressed by employing the 2D
NMR DOSY technique. The technique in combination with an algorithm reported by Evans et al. [20]
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provides a method by which to determine the molecular weight of a compound by its rate of diffusion.
Knowing the molecular weight of the compound isolated from A. chloros allowed for the direct
comparison of the cytotoxicity of the isolated halitoxin to cytotoxicity reports for other halitoxins
of various sizes. Provided here is the first account of the antiviral potential for the halitoxin family
of compounds.
2. Results
2.1. A. chloros Demonstrates Inhibition of West Nile Virus NS3 Protease
Solid phase extracts (SPE) for three biological replicates of A. chloros were generated and
screened for inhibitory activity against the WNV NS3 protease in two orthogonal biochemical assays.
One assay used a QXLTM570/5-TAMRA FRET conjugated substrate and the second used a different,
AMC-conjugated substrate to ensure that a potential hit was not a false positive resulting from the
compound interacting with the fluorophore. SPE fraction 2 (50% Isopropyl Alcohol (IPA)/H2O)
displayed the strongest inhibitory activity in all three biological replicates, and thus was further
screened in a 1:2 dilution series (Figure 1a,b). The results obtained from screening six technical
replicates of the three biological replicates in a serial dilution were averaged and revealed an 80–90%
inhibition of the NS3 protease activity when tested at 75 µg/mL in both assays (Figure 1a,b). The same
set of samples was screened for the ability to inhibit the HCV protease as well as Factor Xa associated
with the serine protease, thrombin (Figure 1c,d). All replicates of fraction 2 failed to show inhibition of
either of the additional targets.
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Figure 1. Percent activit f a series f seri e proteases after treatment with SPE fraction 2 (50%
IPA/H2O) from A. chloros i rt l i che ical a says. (a) Percent activity of the WNV NS3
protease in a biochemical as ay ith 5-TAMRA FRET conjugated substrate; (b) P rcent
activ ty of the rotease in a biochemic l ssay with an AMC conjugated substrate;
(c) Percent activity of the Thrombin-Factor Xa, serine prot ase complex in a biochemical assay with
a 5-FAM FRET conjugated substrate; (d) Percent activity of the HCV NS3/4A protease
in a biochemical assay with a QXL 520/5-FAM FRET conj gated substrate. Err r bars denote
standard deviations.
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2.2. Analytical Chemistry Reveals 3-Alkylpyridinium as the Bioactive Compound
The LC-MS spectrum of the active SPE fraction 2 of A. chloros showed two major species; one with
m/z 190.16, henceforth referred to as compound 1, and the other with m/z 379.31, henceforth referred to
as compound 2 (Figure 2). A compound with the same MS signature has been reported previously [11]
where the species with m/z 190.16 was proposed to be a doubly charged, cyclic, alkylpyridinium
salt (Figure 2, compound 1) and the m/z 379.31 species, a singly charged ion with a terminal olefin
formed by gas phase cleavage (Figure 2, compound 2). Our mass accuracy of <1 ppm is consistent with
these structures, and the observation of these two ions from a single chromatographic peak (Figure S1)
supports their derivation from a single molecule.
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fraction 2 of A. chloros shows an abundance of the linear [ H]+ m/z 379.31 species, r ferred to as
compound 2, as well as the cyclic [ ]2+ doubly charged speci s t z 190.16, ref rr t s 1.
Analysis of NMR spectra of the active SPE fraction 2 identified a molecular fragment with 1H-
and 13C-NMR chemical shifts consistent with the cyclic molecule of compound 1 and very similar
to the 1H-NMR chemical shifts reported previously [11]. The NMR-defined fragment matches only
half of compound 1, but this is to be xpected as compound 1 is symmetrical and the methylenes
in the center of the alkyl chain will be overlapping and difficult to resolve. Interestingly, the peaks
of compound 1 in t e 1D 1H-NMR spectrum (Figure S5) were broad r than the peaks of th solvent
( etha ol-d4, δH 3.31 ppm), suggesting a larger molecular weight for the sample than for the solvent.
Furthermore, the NOESY spectrum (Figure S10) showed negative peaks for the aromatic res nances,
suggesting a large molecular weight, and positive peaks for the aliphatic resonances, indicative of a
small molecular weight. To determine if the negative peaks were due to chemical exchange a ROESY
spectrum (Figure S11) was recorded. The ROESY showed only positive peaks, thereby eliminating the
possibility that chemical exchange produced the negative peaks in the NOESY. Observation of positive
and negative peaks in the NOESY suggests that different parts of the molecule exhibit different rates
f motio , or that the molecule is in dynamic exchange between different oligomeric states.
The prior report of compound 1 was unable to deter ine if the molecule was a polymer or a large
oligomer [11]. Mass spectrometric analysis could conceivably dissociate an oligomer or fragment a
polymer into its monomeric s bunits, and thus not escribe the true size of the molecule. To better
characterize the size of com ound 1, we resorted to NMR techniques that report o the state of the
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molecule in solution. Firstly, a 2D Diffusion Ordered Spectroscopy (DOSY) spectrum was recorded. The
DOSY experiment resolves compounds by their translational diffusion, which can be used to estimate
molecular weight. The DOSY spectrum (Figure 3) resolved the solvent methanol (log(D) =−8.75 m2/s),
a lipid-like compound (log(D) = −9.45 m2/s) and compound 1 (log(D) = −10.05 m2/s). Converting
the diffusion constants to molecular weights using a relationship calibrated with a collection of small
molecules [18] gave an estimated molecular weight for compound 1 of 35,000. This surprisingly large
value prompted us to find another means of estimating the molecular weight.
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Figure 3. 2D DOSY spectrum of active SPE fraction 2. The horizontal axis corresponds to the 1H
spectrum, while the vertical axis corresponds to the logarithm of the translational diffusion rate, D.
Three different species were resolved, the solvent methanol (log(D) =−8.75 m2/s), a lipid like compound
(log(D) = −9.45 m2/s), and the cyclic, alkylpyridinium salt compound 1 (log(D) = −10.05 m2/s).
As a second method to estimate molecular weight of compound 1 we measured 13C T1 and T2
relaxation rates, used these to calculate the rotational diffusion time using known relationships [21],
and then estimated the molecular weight using an empirical relationship derived from isotopically
labeled proteins [22]. Relaxation rates were obtained only for the aromatic pyridinium resonances
as methyl and methylene resonances introduce different relaxation pathways that complicate the
analysis [23]. The 13C T1 and T2 relaxation rates of the aromatic resonance of compound 1 are shown
in Table S3. Converting the relaxation rates to a rotational diffusion time gave a value of 1.08 ns, which
corresponds to a molecular weight of approximately 700.
The discrepancy in molecular weight estimates is likely due to a dynamic equilibrium between
single molecules and large oligomers. In a self-associating system with a range of sizes the DOSY
experiment will emphasize the large oligomers, as the signals from the slower moving, large oligmers
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will be less attenuated than those from the smaller, faster moving oligomers. In the relaxation rate
analysis the opposite is true. Signals from the slow moving, large oligomers will be attenuated more
rapidly than those from the faster, smaller oligomers. Thus, the molecular weights estimated from
the two different methods are likely to be upper and lower bounds on the actual size of the oligomer.
We note that compound 1 was originally proposed to exist as a large oligomer or polymer [11].
In order to confirm that compound 1 was responsible for the WNV NS3 inhibitory activity and
not the lipid contaminant identified in the DOSY, a fraction was collected (Table S1) from the region
of the chromatogram (Figure S3) where compound 1 was present in the greatest relative abundance
and was tested again for WNV NS3 protease inhibition (Figure 4). From this re-evaluation we could
confirm with high certainty that the active compound is compound 1, which inhibits the NS3 protease
up to 95% when screened at a concentration of 2 µg/mL.
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Figure 4. Effect of the purified 3-alkylpyridinium compound 1 from A. chloros on WNV NS3 protease
activity. Error bars denote standard deviations.
2.3. Cytological Profiling Reveals the Bioactive 3-Alkylpyridinium Salt as Negligibly Cytotoxic
In order to compare cellular toxicity of the full SPE fraction 2 (Figure 1 a,b) and the purified
compound (Figure 4), we screened four dilutions (75 µg/mL–9.4 µg/mL) of one of the biological
replicates (BR3) of the full SPE fraction (Figure 1) and four dilutions (2 µg/mL–0.25 µg/mL) of its
resulting NS3 active m/z 190.16 LC-MS focused fraction (Figure 4) on HeLa cells (Figure 5). We used a
High-Content Screening (HCS) cytological profiling strategy that captures a broad panel of cellular
markers to gain insight into the induced toxicity on multiple levels [24]. Compound toxicity is mostly
a combination of various mechanisms, and thus, a unidimensional experimental approach is unlikely
to capture the complexity of the underlying processes. We observed that the overall toxicity profile is
significantly reduced for the focused fraction dilution series in comparison to the dilution series for the
parent SPE fraction. The parent SPE fraction simultaneously affects a multitude of cellular processes
including a marked cell loss at higher concentrations as well as strong activation of NFkB, p53 and
caspase 9. In contrast, the focused fraction shows almost no effect on any of the cellular markers.
The overall concentration of the focused fraction is less than the parent SPE fraction (approximately
2 µg/mL), yet NS3 activity is enhanced, suggesting that the focused fraction is not only a potent
inhibitor of the WNV NS3 protease, but also exhibits negligible cytotoxicity to HeLa cells.
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Figure 5. Cytolological profiles composed of 21 core features of the two parent fraction dilutions
and dilutions of compound 1. Colors indicate positive (yellow) or negative (blue) deviation from the
mean of untreated control cells (value = 1). Full cytological profiles were used for clustering (left).
The dendrogram depicts distances between individual cytological profiles based on Pearson correlation
with average linkage for four dilutions of the parent SPE fraction (BR3_SPEfraction2_concentration)
and four dilutions of the NS3 active fraction isolating compound 1 (NS3acitve_concentraion).
3. Discussion
The halitoxins, presumed polymers of 3-alkylpyridinium fragments, are a group of structurally
diverse natural products that have mainly been isolated from marine sponges. These molecules can be
found as cyclic or linear compounds and as monomeric or as polymeric alkylpyridiniums (poly-APS).
They were first characterized in 1978 [10] for their characteristic toxicity to fish, and since then,
a diversity of biological activities has been observed [11,12,15–18]. In this study, we have identified
and characterized a 3-alkylpyridinium compound (compound 1), which shows inhibitory activity
against the WNV NS3 protease. Davies-Coleman et al. [11] synthesized the cyclic alkylpyridinium
salt and found that on thin-layer chromatography (TLC) it ran much faster than the natural product
they had isolated, leading them to conclude that the natural product was an oligomer or polymer.
To accurately assess the molecular size of our active compound, we used DOSY and relaxation rate
analysis. Our results suggest that the molecule is not a polymer but rather an oligomer, or assembly of
up to 90 molecules. Notably, alkylpyridinum salts are used as surfactants and can form micelles with
as few as 10 or as many as 100 molecules [25].
In our most sensitive assay, using an AMC conjugated substrate, the SPE fraction 2 that contained
compound 1 showed 90% inhibition of the WNV NS3 protease at 75 µg/mL. The same set of samples
was screened for the ability to inhibit the HCV protease, as well as Factor Xa (Figure 1c,d), a serine
protease which leads to blood clot formation by converting prothrombin to thrombin. All replicates
of fraction 2 failed to show inhibition of either of the additional serine protease targets suggesting
specificity for the WNV NS3 serine protease. Instead, in both the HCV and Factors Xa assays there was
an enhancement of the protease activity on the substrate, which suggests that the active compound
could be increasing the activity of these proteases, possibly through a surfactant effect [26–28]. Like
other surfactants, compound 1 most likely exhibits a critical micelle concentration (CMC) where
the molecule shows an abrupt change in solution state according to temperature and electrolyte
concentration. Additional serine protease targets should be screened to determine an exclusive
specificity of the active compound for the WNV NS3 protease.
To gain insight into toxicity of compound 1, we employed a High-Content Screening (HCS)
cytological profiling strategy on HeLa cells assaying SPE parent fraction dilutions and dilutions of
compound 1 (Figure 5). The parent fraction that contains compound 1 showed cytotoxicity for the four
dilutions of 75 µg/mL to 9.4 µg/mL when screened using the HCS platform that assesses a number of
cellular features commonly affected by toxic compounds (Figure 5). After the LC-MS flow-through
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focused on the time point where compound 1 is present in the greatest relative abundance (Figure S1),
and testing again in the WNV NS3 assay with an AMC conjugated substrate, we observed that the
compound 1 focused fraction, screened at 2 µg/mL, is most likely responsible for the observed WNV
NS3 inhibition (Figure 4). This same focused sample was then screened on the HCS platform and
no longer showed the toxicity profile associated with the SPE parent fraction (Figure 5). Our HCS
results show that the fraction collected from LC-MS is nontoxic at concentrations below 9.4 µg/mL
(screened at approximately 2 µg/mL), whereas, the parent fraction is toxic (Figure 5). This is in
accordance with previous reports relating compound size and treatment amount to toxicity for the
halitoxin family [15,17,29]. Interestingly, the parent fraction strongly affects a variety of cellular
processes, even at concentrations where no reductions in cell numbers were observed, including the
induction of several well-known markers of toxicity, including activation of NFkB, p53, caspase 9
as well as effects on mitochondria, ER, and the cytoskeleton, whereas the focused fraction does not.
In addition, at the higher concentrations of the parent fraction with markedly reduced cell counts,
we observed an increased intensity of the membrane marker which might indicate membrane-targeting
activity of the active compound. The observed reduction in toxicity of the focused fraction could be
due to the reduced concentration of the NS3 protease-inhibiting material; or this concentration may
not be achieving the critical micelle concentration and thereby generating a large enough oligomer
capable of permeating cell membranes. Future work to evaluate this compound for its potential as a
WNV antiviral would require a cell-based assay to determine compound efficacy in addition to X-ray
crystallography work to fully understand the mechanism of binding for this compound to the WNV
NS3 protease.
4. Materials and Methods
4.1. A. chloros Sponge Collection
The Amphimedon chloros specimens were collected using gardening shears from Inner Fsar reef
(22◦14′37.61′′ N; 39◦00′28.03′′ E) off the coast of KAUST (Red Sea, Saudi Arabia) at 12 meters depth
using SCUBA. The samples were briefly rinsed with PBS, wrapped in foil and placed on ice, then
frozen to −80 ◦C until processing.
4.2. A. chloros Sponge Extraction
Small sponge specimens of 4–10 grams in weight were ground using a mortar and pestle, and then
extracted with 15 mL of methanol overnight at 4 ◦C. The following day, the methanol extract was dried
onto 150 mg of Diaion HP20SS beads in a CentriVap complete vacuum concentrator (Labconco, Kansas
City, MO, USA) on low, the beads were loaded into a 25 mL Flash Cartridge (Sorbtech, Norcross, GA,
USA) with 0.795 diameter Frits (Sorbtech), desalted with deionized water (15 mL, FW1, FW2), and then
eluted with 15 mL of solvent in the following series: 25% IPA/H2O, 50% IPA/H2O, 75% IPA/H2O,
100% MeOH [27].
4.3. Liquid Chromatography-Mass Spectrometry (LC-MS) of A. chloros SPE Fraction
Liquid chromatography-mass spectrometry (LC-MS) was carried out on the Thermo LTQ Orbitrap
instrument (Thermo Fisher Scientific, Waltham, MA, USA) in positive mode using electrospray
ionization. The 10 µL of solid phase extracted (SPE) sponge material was separated using a ZORBAX
Eclipse XDB-C18 LC column (Agilent Technologies, Santa Clara, CA, USA), 4.6 mm, 150 mm, 5 µm
with the gradient displayed in Table S1 and a flow rate of 0.800 mL/min. 10 µL of solid phase extract
was also directly injected and the desired compound was collected at a specific run time to obtain a
concentrated sample of m/z 190.16 (Figure 2, compound 1).
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4.4. Nuclear Magnetic Resonance (NMR) of A. chloros 3-Alkyl Pyridinium
The isolated 3-alkylpyridinium compound (12 mg) dissolved in methanol-d4 was used to collect
NMR spectra at 298 K on Avance III 600 MHz spectrometer (Bruker, Billerica, MA, USA). Standard
Bruker pulse sequences were employed. Spectra were referenced to the residual methanol solvent
resonance (3.31 ppm for 1H and 49.0 for 13C). The HMBC was optimized for 8 Hz couplings, the NOESY
used a 500 ms mixing time, and the ROESY used a 300 ms mixing time. The DOSY experimental data
were obtained using bipolar gradient pulse pairs and two spoil gradients (ledbpgp2s in the standard
Bruker pulse sequence library). A smoothed square shape of 2.4 ms duration was used for the bipolar
gradients; its strength was increased linearly from 2% to 95% of the maximum gradient strength of
53 G/cm, acquiring 32 steps of gradient levels. A gradient recovery delay of 2 ms was used and
the diffusion time was set to 300 ms (D20 of 300 ms and a P30 of 2400 µs). Each spectrum collected
128 transients with a 5 s recycle delay for a total experimental time of 7.5 h. The spectrum was
processed and analyzed using TopSpin 2.1 (Bruker). 13C relaxation rate spectra were measured in an
interleaved fashion. For T1s 13 delays were used (10, 20, 30, 40, 50, 70, 100, 150, 200, 300, 500, 700 and
1000 ms). For the T2s 11 delays were used (22.4, 44.8, 67.2, 89.6, 112.0, 134.0, 179.0, 246.0, 291.0, 381.0
and 493.0 ms). Spectra were processed with the software NMRpipe [22] and rates were extracted using
the software Sparky [23].
4.5. West Nile Virus (WNV) NS3 Protease Inhibition Assay
The West Nile Virus NS3 protease inhibition assay was carried out using the commercial kit
SensoLyte®) 440 West Nile Virus Protease Assay Kit (AnaSpec, San Jose, CA, USA). The protease
is a truncated form of West Nile NS3 protease (residues 1–186). Connected to it is NS2B cofactor
(residues 49–96) by the linker sequence, GGGGSGGGG. Protease activity was assessed by its
ability to cleave the fluorogenic peptide Pyr-RTKR-AMC, and the subsequent production of free
AMC (7-amino-4-methylcoumarin) fluorophores monitored at 354 nm excitation wavelength and
442 nm emission wavelength. As well, a second orthogonal substrate cleavage experiment was
carried out, which used a FRET conjugated substrate. In this assay, West Nile Virus NS3 protease
inhibition was assayed using the commercial kit SensoLyte®570 West Nile Virus Protease Assay Kit
(AnaSpec). Here, WNV protease inhibitors are assessed by their ability to inhibit the cleavage of the
QXLTM570/5-TAMRA FRET substrate by the protease. Upon cleavage into two separate fragments
by the WNV NS3 protease, the fluorescence of 5-TAMRA can be monitored at excitation/emission =
540 nm/575 nm. All extracts and controls were performed with three replicates in a 384-well plate
format, each with a total reaction mixture of 33 µL. To begin, the test extracts and protease solution were
incubated at 37 ◦C for 10 min before the addition of the pre-heated substrate. After substrate addition
and gentle mixing the reaction was incubated at 37 ◦C for one h. The fluorophore was detected with
the use of a SpectraMax®Paradigm®Multi-mode Microplate Detection Platform (Molecular Devices,
Sunnyvale, CA, USA) by scanning at the wavelength associated with the respective assay.
4.6. HCV NS3/4A Protease Inhibition Assay
The HCV NS3/4A protease inhibition assay was carried out using the commercial SensoLyte®520
HCV Protease Assay Kit (AnaSpec). The HCV NS3/4A protease is a 217 amino acid fusion protein
(22.7 kDa) with NS4A co-factor fused to the N-terminus of NS3 protease domain. HCV NS3/4A
protease activity was assessed by its ability to cleave the fluorogenic FRET peptide, and the subsequent
unquenching by QXL 520 quencher of the 5-FAM fluorophore, which emits fluorescence. All extracts
and controls were performed with three replicates in a 384-well plate format, each with a total reaction
mixture of 18 µL. To begin, the test extracts and protease solution were incubated at room temperature
for 10 min before the addition of the substrate. After substrate addition and gentle mixing the reaction
was incubated at room temperature for one hour. The fluorophore was detected with the use of a
Molecules 2018, 23, 1472 10 of 12
SpectraMax®Paradigm®Multi-mode Microplate Detection Platform (Molecular Devices) by scanning
at 490 nm excitation wavelength and 520 nm emission wavelength.
4.7. Thrombin Serine Protease Inhibition Assay
The Factor Xa inhibition assay was carried out using a commercial SensoLyte®520 Factor Xa
Assay Kit (AnaSpec). The Factor Xa activity was assessed by its ability to cleave the fluorogenic FRET
peptide and the subsequent unquenching by QXL 520 quencher of the 5-FAM fluorophore, which
emits fluorescence. All extracts and controls were performed with three replicates in a 384-well plate
format, each with a total reaction mixture of 12.5 µL. To begin, the test extracts and Thrombin/Factor
Xa solution were incubated for five minutes then the substrate was added. After substrate addition
and gentle mixing the reaction was incubated at room temperature for one hour. The fluorophore
was detected with the use of a SpectraMax®Paradigm®Multi-mode Microplate Detection Platform
(Molecular Devices) by scanning at 490 nm excitation wavelength and 520 nm emission wavelength.
4.8. Cytological Profiling by High-Content Screening (HCS)
Cytological profiling was performed as recently described [24,30]. Briefly, HeLa cells were tested in
black µClear CELLSTAR 384-well plates (Greiner Bio-One, Kremsmünster, Austria) at an approximate
density of 2000 cells per well in a volume of 25 µL of cell culture medium with re-dissolved fractions
in 4 replicates. 24 h after treatment, four different cell-staining protocols (panels) were used to stain for
10 cellular targets (cell count/cell loss; cell cycle; whole cell morphology; nuclear morphology; actin;
tubulin; mitochondria; lysosomes; endoplasmic reticulum; plasma membrane; activation of NFkB, p53
and caspase 9). For High-Content Analysis, the CellomicsArrayScan VTI (Thermo Fisher Scientific,
Waltham, MA, USA) platform equipped with a 10x objective (Zeiss Plan Neofluar, NA 0.3, ZEISS,
Oberkochen, Germany) was used. Images were analyzed using the Compartmental Analysis Bio
Application software (Cellomics, Thermo Fisher Scientific). At least 500 valid objects were analyzed
per well. Cell cycle analysis and analysis of cell loss were accomplished by using the Cell Cycle Bio
Application (Cellomics) using a minimum of 2000 valid objects.
Supplementary Materials: The following are available online. Figure S1. Mass spectra of ions from SPE fraction 2
active against VNV NS3; Figure S2. Extracted LC-MS chromatrograms; Figure S3. LC-MS direct injection collection
of concentrated m/z 379 NS3 active compound; Table S1. LC-MS gradient used to isolate and characterize the
bioactive compound of A. chloros SPE fraction 2; Figure S4. Fragment of compound 1 defined by NMR; Table S2.
Chemical shift assignments of compound 1; Figure S5. 1D 1H NMR spectrum of active SPE fraction 2; Table S3.
13C T1 and T2 relaxation rates; Figure S6. 1H-1H DQF-COSY spectrum of compound 1; Figure S7. 1H-13C HSQC
spectrum of compound 1; Figure S8. 1H-13C H2BC spectrum of compound 1; Figure S9. 1H-13C HMBC spectrum
of compound 1; Figure S10. 1H-1H NOESY spectrum of compound 1; Figure S11. 1H-1H ROESY spectrum of
compound 1.
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